Multiple myeloma is a cancer of plasma cells, the white blood cells responsible for producing antibodies in the bone marrow. Understanding its origins requires examining an interplay of genetic mutations, chromosomal abnormalities, inherited predispositions, and environmental exposures that collectively drive the disease.
Key Takeaways
- Multiple myeloma arises from abnormal plasma cells in the bone marrow, often preceded by a precursor condition called MGUS.
- Specific gene mutations and chromosomal rearrangements are central drivers of disease development.
- A small proportion of cases show familial clustering, suggesting a hereditary component, though no single causative gene has been confirmed.
- Environmental exposures, including radiation, certain chemicals, and obesity, meaningfully raise disease risk.
- Age, sex, and race are non-modifiable factors that influence overall risk, with Black Americans diagnosed at nearly twice the rate of white Americans.
What Causes Multiple Myeloma? Exploring Genetic and Environmental Factors
Multiple myeloma develops when plasma cells in the bone marrow accumulate DNA damage and begin dividing uncontrollably, crowding out healthy blood cells and producing abnormal proteins. This process rarely happens overnight. Most cases are preceded by a benign condition known as monoclonal gammopathy of undetermined significance (MGUS), which progresses to myeloma in roughly 1% of affected individuals per year, according to the Mayo Clinic. Understanding the full picture of causation means recognizing that no single factor acts alone.
The disease results from a cascade of molecular events. Initially, a single abnormal plasma cell acquires a mutation that gives it a survival advantage. Over time, additional genetic errors accumulate, allowing the clone to evade immune surveillance, stimulate its own growth signals, and resist programmed cell death. This stepwise progression from MGUS to smoldering myeloma and then to active disease reflects the gradual buildup of damage rather than a single triggering moment.
According to the American Cancer Society, approximately 35,780 new cases of multiple myeloma are estimated to be diagnosed in the United States in 2024, making it one of the more common blood cancers. The disease is more prevalent in older adults, with the median age at diagnosis being around 70. This age pattern suggests that cumulative genetic and environmental damage over a lifetime plays a substantial role in disease onset.
Key Gene Mutations and Chromosomal Changes That Trigger Multiple Myeloma
Multiple myeloma gene mutations and triggers encompass a broad range of molecular alterations, many of which disrupt how plasma cells grow, survive, and respond to normal regulatory signals. Among the most common chromosomal events is a translocation involving the immunoglobulin heavy chain gene on chromosome 14. This rearrangement brings oncogenes—genes that promote cell division—under the control of highly active promoters, causing them to be expressed at abnormally high levels. Translocations involving chromosomes 4, 11, and 16 are particularly well-documented in myeloma biology.
Hyperdiploidy, a condition in which cells contain extra copies of certain chromosomes, is found in roughly half of all myeloma cases. This abnormal chromosome number appears to confer survival advantages to malignant plasma cells. In contrast, other patients show deletions—particularly of chromosome 17p, which harbors the TP53 tumor suppressor gene—leading to the loss of one of the cell’s key braking mechanisms. Deletion of 17p is associated with more aggressive disease behavior and poorer treatment outcomes.
Mutations in genes such as KRAS, NRAS, and BRAF are also frequently detected and activate the RAS-MAPK signaling pathway, which drives uncontrolled cell proliferation. Epigenetic changes—modifications that alter gene expression without changing the DNA sequence itself—further contribute by silencing tumor suppressor genes. Collectively, these alterations create a permissive cellular environment in which malignant plasma cells thrive. Research continues to map the full mutational landscape of the disease, and next-generation sequencing has revealed that each patient’s myeloma carries a unique combination of these changes.
Is Multiple Myeloma Hereditary? Understanding Familial and Genetic Risk
Multiple myeloma genetic risk factors include both inherited susceptibilities and acquired mutations. While the vast majority of cases are not directly inherited in the way that some cancers are, evidence of familial clustering is well-established. First-degree relatives of individuals with multiple myeloma face a two- to four-fold higher risk of developing the disease themselves, compared with the general population. This elevated risk also extends to MGUS, reinforcing the idea that a heritable predisposition affects early steps in the disease process.
Genome-wide association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs)—common genetic variants—that modestly but consistently increase susceptibility to myeloma. Variants near genes involved in immune regulation and DNA repair have drawn particular attention. None of these variants is sufficient to cause myeloma on its own; rather, they create a background of elevated risk that interacts with environmental and stochastic factors. No high-penetrance gene equivalent to BRCA1 in breast cancer has been identified for multiple myeloma to date.
Race and ethnicity also reflect underlying genetic variation in risk. Black Americans develop multiple myeloma at roughly twice the incidence rate of white Americans, according to data published by the American Cancer Society and the National Cancer Institute. This disparity cannot be fully explained by socioeconomic or healthcare access factors alone, suggesting that population-level genetic differences in immune function or plasma cell biology may contribute. Research into these disparities remains an active and important area of study.
| Risk Factor Type | Example | Level of Evidence |
|---|---|---|
| Chromosomal abnormality | IgH translocation, 17p deletion, hyperdiploidy | Well-established |
| Oncogene mutation | KRAS, NRAS, BRAF | Well-established |
| Familial predisposition | First-degree relative with myeloma or MGUS | Moderate–strong |
| Inherited genetic variants | SNPs identified via GWAS | Moderate |
| Racial/ethnic background | African American ancestry | Strong (epidemiological) |
| Chemical/radiation exposure | Benzene, ionizing radiation | Moderate–strong |
| Obesity | Elevated BMI in adulthood | Moderate |
Lifestyle, Occupational Exposures, and Other Factors That Increase Risk
Environmental causes of multiple myeloma have been investigated across numerous epidemiological studies, and several exposures have emerged as meaningful contributors to disease risk. Ionizing radiation is one of the most firmly established external risk factors. Survivors of the atomic bombings in Japan, as well as workers in certain nuclear industries, have shown elevated rates of multiple myeloma, pointing to radiation’s capacity to induce the kinds of DNA damage that drive malignant transformation in plasma cells.
Occupational chemical exposures represent another important category of risk. Benzene, a solvent found in petroleum products and certain industrial settings, has been linked to multiple blood cancers, including myeloma. Agricultural workers exposed to pesticides and herbicides, as well as workers in the rubber and leather industries, have been studied for elevated myeloma rates in several cohort analyses. The International Agency for Research on Cancer (IARC) classifies certain pesticides as probable or possible carcinogens, and their role in lymphoid malignancies continues to be examined.
Beyond occupational hazards, modifiable lifestyle factors also influence risk. Obesity is associated with a moderately increased risk of multiple myeloma, likely because excess adipose tissue promotes chronic low-grade inflammation and alters levels of cytokines—such as interleukin-6—that directly stimulate plasma cell growth. The following factors are associated with an increased likelihood of developing the disease:
- Age over 65, as cumulative DNA damage increases with time
- Male sex, as men are diagnosed at slightly higher rates than women
- Obesity or being overweight in middle and later adulthood
- A personal history of MGUS or smoldering myeloma
- Long-term occupational exposure to benzene, pesticides, or ionizing radiation
Multiple myeloma risk factors and causes do not operate in isolation. In most patients, disease development reflects the convergence of inherited genetic susceptibility, acquired somatic mutations, and external environmental exposures over many years. This complexity underscores why no single preventive measure can eliminate risk, though minimizing known exposures—such as occupational chemicals and maintaining a healthy weight—remains a reasonable and evidence-informed approach to reducing personal risk where possible.
Frequently Asked Questions
Can multiple myeloma be prevented?
There is currently no proven strategy to prevent multiple myeloma, as many of its root causes—including chromosomal abnormalities and inherited susceptibility—cannot be controlled. However, limiting exposure to known risk factors such as benzene and ionizing radiation, maintaining a healthy body weight, and receiving regular monitoring if diagnosed with MGUS may reduce progression risk. Anyone with a family history of the disease should discuss appropriate screening with a healthcare provider.
Does having MGUS mean I will develop multiple myeloma?
Not necessarily. MGUS progresses to multiple myeloma or a related blood disorder in approximately 1% of cases per year, meaning the majority of people with MGUS never develop active cancer. However, MGUS requires regular monitoring because it is considered the most common precursor condition. Risk of progression depends on factors such as the type and quantity of the abnormal protein and the ratio of certain immune cells in the bone marrow.
Are there specific blood tests that identify genetic risk for multiple myeloma?
Standard blood tests do not screen for inherited genetic susceptibility to multiple myeloma. Specialized cytogenetic and molecular testing—such as fluorescence in situ hybridization (FISH) and next-generation sequencing—are used after diagnosis to identify chromosomal changes and gene mutations within the tumor cells themselves. These tests guide treatment decisions rather than screen healthy individuals. Genetic counseling may be appropriate for families with multiple affected members to explore inherited risk patterns.
